![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Efficacy and Safety of Dolutegravir (DTG) in Hepatitis (HBV or HCV) Co-infected Patients: Results From the Phase 3 Program
|
|
|
Reported by Jules Levin
20th International AIDS Conference; July 20-25, 2014; Melbourne, Australia
S Min,1 J Roberts,2 S Almond,2 L Curtis,3 C Stainsby,3 J Lim,4 B Wynne,5 G Nichols1
1-5GlaxoSmithKline, 1ID Medicine Development, Research Triangle Park, NC, USA; 2Statistics, Mississauga, Canada; 3Global Clinical Safety and Pharmacovigilance, Stockley Park, UK; 4Statistics, Stockley Park, UK; 5ID Medicine Development, Upper Providence, PA, USA
![IAC1.gif](../images/072814/072814-12/IAC1.gif)
![IAC2.gif](../images/072814/072814-12/IAC2.gif)
![IAC3.gif](../images/072814/072814-12/IAC3.gif)
![IAC4.gif](../images/072814/072814-12/IAC4.gif)
![IAC5.gif](../images/072814/072814-12/IAC5.gif)
![IAC6.gif](../images/072814/072814-12/IAC6.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|